Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients with AML, ALL and MDS compared to a conventional allogeneic hematopoietic stem cell ...
TipRanks on MSN
Cynata completes enrollment in phase 2 aGVHD trial
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market ...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer-reviewed comparative analysis of efficacy ...
MedPage Today on MSN
Potential Game-Changing Impact on Mismatched Unrelated Blood Cell Transplantation
Patients with <7/8 transplants had a 1-year survival of 85.6% versus 78.6% for those who received better-matched donor cells.
Among patients experiencing chronic graft-versus-host disease (cGVHD), the transition of treatment with Niktimvo (axatilimab) ...
A specific graft-versus-host disease prophylaxis regimen may expand allogeneic hematopoietic stem cell transplant access to ...
A "hybrid" immune system approach may prevent or cure Type 1 diabetes (T1D) by combining blood stem cell and islet cell transplants. The method uses a nonmyeloablative conditioning regimen to prevent ...
Treatment with Zervyteg (MaaT013) generated encouraging results and demonstrated an acceptable safety profile in patients with acute graft-vs-host disease that affects the gastrointestinal tract and ...
The results of the Precision-T Phase 3 study of investigational allogeneic T-cell immunotherapy, Orca-T, were published in the journal Blood.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback